Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q3 FY22 results · Oct–Dec 2021
Tatva Chintan Pharma Chem reported revenue from operations of ₹104.67 crore and net profit of ₹22.81 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 104.67 | — | — | 123.61 | −15.3% |
| Other income | 4.72 | — | — | 2.80 | +68.5% |
| Total income | 109.39 | — | — | 126.42 | −13.5% |
| Profit before tax | 25.47 | — | — | 35.42 | −28.1% |
| Net profit for the period | 22.81 | — | — | 32.41 | −29.6% |
| EPS, basic (₹) | 10.29 | — | — | 15.02 | −31.5% |
| Net margin (%) | 21.8 | — | 26.2 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 101.59 | — | — | 116.69 | −12.9% |
| Other income | 5.08 | — | — | 2.60 | +95.7% |
| Total income | 106.67 | — | — | 119.28 | −10.6% |
| Profit before tax | 24.77 | — | — | 33.55 | −26.2% |
| Net profit for the period | 22.43 | — | — | 30.72 | −27.0% |
| EPS, basic (₹) | 10.12 | — | — | 14.24 | −28.9% |
| Net margin (%) | 22.1 | — | 26.3 |
Consolidated
- Filed with BSE
- 18 Jan 2022, 08:19 IST
- Board meeting
- 17 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Jan 2022, 08:19 IST
- Board meeting
- 17 Jan 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE